💊 Insilico wants to build “longevity vaccines” with AI

Insilico Medicine has launched a new research initiative aimed at using AI and programmable RNA to target some of the earliest cellular drivers of aging.

Instead of treating diseases after damage has accumulated, the company wants to use a single, self-limiting treatment to help the body’s own immune system identify and eliminate problematic cells.

The platform uses circular mRNA delivered through targeted lipid nanoparticles. The genetic instructions would temporarily equip a patient’s own T cells to recognize and clear specific cell populations, including senescent cells, fibrotic cells and autoreactive immune cells.

Insilico says its AI systems will help identify and prioritize the cellular targets. The first focus is immune-system rejuvenation by removing senescent lymphocytes, with metabolic dysfunction and other age-related conditions also being explored.

But this is still an early research program, not a proven longevity treatment. Insilico has not yet disclosed program-specific safety or efficacy data or a clinical trial timeline.

Source.

@aipost 🏴